公开(公告)号：US08277820B2

公开(公告)日：2012-10-02

申请号：US10590896

申请日：2005-02-08

申请人： Toshihiro Ushijima ,  Masashi Sakaguchi ,  Eiji Tokunaga

发明人： Toshihiro Ushijima ,  Masashi Sakaguchi ,  Eiji Tokunaga

IPC分类号： A61K39/00 ,  A61K39/38 ,  A61K39/02 ,  C12P21/06 ,  C12N15/09

CPC分类号： C07K14/195 ,  A61K38/00 ,  A61K39/00

摘要： A variant of Erysipelothrix rhusiopathiae surface protective antigen SpaA protein or of a shortened form of SpaA (ΔSpaA) in which a portion of SpaA protein is deleted for protection from Erysipelothrix rhusiopathiae infection and a process for preparing the same are provided. Introduction of amino acid substitution at a specific site in the amino acid sequence of SpaA or ΔSpaA protein provides a variant of SpaA or ΔSpaA protein which is immunogenic and is expressed in E. coli as inclusion bodies. The variant of SpaA or ΔSpaA protein of the present invention may easily be recovered and purified since it is expressed in E. coli as inclusion bodies.

摘要翻译： 提供了Erysillolothrix rhasiopathiae表面保护性抗原SpaA蛋白或SpaA（＆Dgr。SpaA）的缩写形式的一种变体，其中一部分SpaA蛋白被缺失以防止欧莱氏杆菌性鼻病毒感染及其制备方法。 在SpaA或＆Dgr; SpaA蛋白的氨基酸序列中的特定位点引入氨基酸取代提供了SPAA或＆Dgr; SpaA蛋白的变体，其是免疫原性的并且在大肠杆菌中以包涵体表达。 本发明的SpaA或＆Dgr; SpaA蛋白质的变体可以容易地回收和纯化，因为其在大肠杆菌中作为包涵体表达。

公开(公告)号：US08106015B2

公开(公告)日：2012-01-31

申请号：US12596741

申请日：2008-04-18

申请人： Junichi Matsuda ,  Kazuyoshi Kaminaka ,  Chikateru Nozaki

发明人： Junichi Matsuda ,  Kazuyoshi Kaminaka ,  Chikateru Nozaki

IPC分类号： A61K38/17 ,  A61K39/00 ,  A61P25/00 ,  A61P37/04 ,  C07K14/435

CPC分类号： A61K39/0007 ,  A61K31/711 ,  C07K14/4711

摘要： An object of the present invention is to provide a safe and effective method for enhancing an immune response and a medicament for preventing or treating Alzheimer disease comprising amyloid β peptide that induces an enhanced immune response. An amyloid β peptide or a portion thereof with addition or insertion of cysteine and a method for enhancing an immune response using the peptide or a method for enhancing an immune response using the peptide together with an adjuvant. A medicament for preventing or treating Alzheimer disease comprising an amyloid β peptide or a portion thereof that induces an enhanced immune response. A DNA vaccine, that may have the same effect, comprising the gene encoding an amyloid β peptide or a portion thereof that induces an enhanced immune response with addition or insertion of cysteine.

摘要翻译： 本发明的目的是提供一种用于增强免疫应答的安全有效的方法和用于预防或治疗阿尔茨海默氏病的药物，其包括淀粉样蛋白 诱导增强的免疫应答的肽。 淀粉样蛋白 肽或其部分，其中加入或插入半胱氨酸，以及使用肽增强免疫应答的方法或使用肽与佐剂一起增强免疫应答的方法。 一种用于预防或治疗阿尔茨海默病的药物，其包含淀粉样蛋白 肽或其部分诱导增强的免疫应答。 可能具有相同作用的DNA疫苗，其包含编码淀粉样蛋白的基因; 肽或其部分，其通过加入或插入半胱氨酸诱导增强的免疫应答。

公开(公告)号：US20100113338A1

公开(公告)日：2010-05-06

申请号：US11993580

申请日：2006-06-21

申请人： Masanao Watanabe ,  Kazuo Tsubota ,  Masaki Hirashima ,  Chikateru Nozaki

发明人： Masanao Watanabe ,  Kazuo Tsubota ,  Masaki Hirashima ,  Chikateru Nozaki

IPC分类号： A61K38/16 ,  C07K14/00 ,  A61P27/02

CPC分类号： A61K38/1761 ,  A61K9/0048

摘要： Disclosed is a novel composition for the treatment of a corneal/conjunctival disease. A prophylactic or therapeutic agent for a corneal/conjunctival disease comprising selenoprotein P as an active ingredient, more specifically a prophylactic or therapeutic agent for a corneal/conjunctival disease such as dry eye, keratoconjunctivitis sicca, superficial punctate keratopathy, corneal erosion or corneal ulcer comprising selenoprotein P as an active ingredient, particularly a prophylactic or therapeutic agent for a corneal/conjuncrtival disease such as dry eye, keratoconjunctivitis sicca, superficial punctate keratopathy, corneal erosion or corneal ulcer accompanied by a corneal/conjunctival epithelial discorder.

摘要翻译： 公开了用于治疗角膜/结膜疾病的新型组合物。 一种用于角膜/结膜疾病的预防或治疗剂，其包含硒蛋白P作为活性成分，更具体地，涉及用于角膜/结膜疾病如干眼症，圆锥形结膜炎丝氨酸，浅表性点状角膜病，角膜侵蚀或角膜溃疡的预防或治疗剂，其包括 硒蛋白P作为活性成分，特别是用于角膜/结膜性疾病例如干眼症，透角圆锥形结膜炎，浅表性点状角膜病变，伴随角膜/结膜上皮发生器的角膜侵蚀或角膜溃疡的预防或治疗剂。

公开(公告)号：US07667009B2

公开(公告)日：2010-02-23

申请号：US10555883

申请日：2004-04-14

申请人： Satoshi Koyanagi ,  Kenjiro Kawatsu ,  Toshio Murakami ,  Yoshinobu Miyatsu ,  Toshihiro Maeda ,  Hiroshi Mizokami

发明人： Satoshi Koyanagi ,  Kenjiro Kawatsu ,  Toshio Murakami ,  Yoshinobu Miyatsu ,  Toshihiro Maeda ,  Hiroshi Mizokami

IPC分类号： A23J1/00

CPC分类号： C07K14/43531 ,  A61K38/00 ,  A61K39/00

摘要： A method for purifying a modified major mite allergen obtained by the genetic recombination technique and a purified modified major mite allergen obtained by said method for purification are provided. A method for purifying a modified major mite allergen obtained by the genetic recombination technique, which comprises the purification steps: (1) Washing and recovering inclusion bodies containing a modified major mite allergen obtained by the genetic recombination technique with MF membrane; (2) Dissolving said inclusion bodies followed by refolding; (3) Concentrating a solution containing the modified major mite allergen with simultaneous removal of low molecular weight components with ultrafiltration membrane; (4) Recovering the modified major mite allergen in non-adsorbed fractions with an anion exchanger; (5) Recovering the modified major mite allergen in adsorbed fractions with a hydrophobic gel; and (6) Recovering the modified major mite allergen in adsorbed fractions with an anion exchanger, and a modified major mite allergen with high purity obtained by said method for purification.

摘要翻译： 提供了通过遗传重组技术获得的改良的主要螨变应原的纯化方法和通过所述纯化方法获得的纯化的改良的主要螨变应原。 一种用于纯化通过遗传重组技术获得的改性主要螨变应原的方法，其包括纯化步骤：（1）洗涤并回收含有通过MF膜的遗传重组技术获得的修饰的主要螨变应原的包含体; （2）溶解所述包涵体，然后重折叠; （3）浓缩含有改性主要螨变应原的溶液，同时用超滤膜除去低分子量成分; （4）用阴离子交换剂回收未吸附级分的改性主要螨变应原; （5）用疏水凝胶回收吸附级分中的改性主要螨变应原; 和（6）用阴离子交换剂回收吸附级分中的改性主要螨变应原，以及通过所述纯化方法获得的具有高纯度的改性主要螨变应原。

公开(公告)号：US20090181446A1

公开(公告)日：2009-07-16

申请号：US12300625

申请日：2007-05-11

申请人： Toshinobu Nouchi ,  Kiyoto Nishiyama ,  Keishin Sugawara

发明人： Toshinobu Nouchi ,  Kiyoto Nishiyama ,  Keishin Sugawara

IPC分类号： C12N7/00

CPC分类号： C12N7/00 ,  A61K2039/525 ,  C12N2501/70 ,  C12N2760/16051

摘要： A method for producing influenza virus on large scale is provided. A method for propagating influenza virus which comprises, after removing or decreasing a trypsin inhibitor secreted into culture of MDCK cells (cell line derived from dog kidney) by washing with a culture medium or a buffer, inoculating influenza virus into said cells and culturing said influenza virus-inoculated cells in a culture medium supplemented with trypsin.

摘要翻译： 提供了大规模生产流感病毒的方法。 一种传播流感病毒的方法，其特征在于，在通过用培养基或缓冲液洗涤除去或降低分泌到MDCK细胞培养物（来自狗肾的细胞系）中的胰蛋白酶抑制剂后，将流感病毒接种入所述细胞并培养所述流感 病毒接种的细胞在补充有胰蛋白酶的培养基中。

公开(公告)号：US20080131422A1

公开(公告)日：2008-06-05

申请号：US11579072

申请日：2005-04-21

申请人： Kazuhisa Sugimura ,  Toshihiro Nakashima

发明人： Kazuhisa Sugimura ,  Toshihiro Nakashima

IPC分类号： A61K39/00 ,  C07K16/00 ,  C07H21/04 ,  C12N15/00 ,  A61P43/00 ,  C12N5/00 ,  C12P21/04 ,  G01N33/53

CPC分类号： G01N33/6896 ,  A61K31/7088 ,  A61K48/00 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/622 ,  G01N2333/4709 ,  G01N2800/2821

摘要： A human anti-amyloid β peptide (hereinafter referred to as “Aβ”) antibody that binds to Aβ to thereby inhibit aggregation of Aβ molecules, and a fragment of said antibody are provided. The antibody and a fragment thereof according to the present invention, comprising a variable region of a human-derived anti-Aβ antibody, strongly reacts with Aβ to thereby inhibit its aggregation and hence may be used as a medicament for the prophylaxis and treatment of Alzheimer dementia.

摘要翻译： 提供了与Abeta结合从而抑制Abeta分子聚集的人抗淀粉样蛋白β肽（以下称为“Abeta”）抗体和所述抗体的片段。 包含人源抗Abeta抗体的可变区的本发明的抗体及其片段与Abeta强烈反应从而抑制其聚集，因此可用作预防和治疗阿尔茨海默病的药物 痴呆。

公开(公告)号：US20060281903A1

公开(公告)日：2006-12-14

申请号：US10552369

申请日：2004-04-08

申请人： Rikiichi Tagawa ,  Yoshihiro Hayase ,  Kota Maemura ,  Hisashi Tanigawa

发明人： Rikiichi Tagawa ,  Yoshihiro Hayase ,  Kota Maemura ,  Hisashi Tanigawa

IPC分类号： C07K14/765

CPC分类号： C07K14/76 ,  A61K38/38 ,  B01D61/147

摘要： An albumin preparation may be produced efficiently on a commercial basis that has reduced possibility of contamination of infectious viruses and has high safety and stability. The process according to the present invention comprises a step of filtration of a serum albumin-containing solution with a virus-removing membrane preferably with a pore size of 10 to 20 nm. In particular, said filtration is performed before heat treatment for inactivation of viruses. In a more preferable embodiment, said serum albumin-containing solution is treated with an anion exchanger and/or a prefilter before a step of said filtration.

摘要翻译： 可以商业上有效地生产白蛋白制剂，其具有降低的感染性病毒污染的可能性并且具有高的安全性和稳定性。 根据本发明的方法包括用优选具有10至20nm的孔径的病毒除去膜过滤含血清白蛋白的溶液的步骤。 特别地，所述过滤在用于灭活病毒的热处理之前进行。 在更优选的实施方案中，所述含血清白蛋白的溶液在所述过滤步骤之前用阴离子交换剂和/或预过滤器处理。

公开(公告)号：US20060094650A1

公开(公告)日：2006-05-04

申请号：US10540852

申请日：2003-12-26

申请人： Kenji Okajima ,  Fujio Matsuo ,  Hiroyuki Sutoh ,  Yoichi Ogata ,  Tomohiro Nakagaki

发明人： Kenji Okajima ,  Fujio Matsuo ,  Hiroyuki Sutoh ,  Yoichi Ogata ,  Tomohiro Nakagaki

IPC分类号： A61K38/17

CPC分类号： A61K38/4866

摘要： A medicament for improving prognostic survival in therapy of malignant tumor is provided that may improve prognostic survival in DIC patients where the basal disease is malignant tumor, especially malignant tumor in hematopoietic organs. The medicament according to the invention comprises as a main active ingredient Activated Protein C, which is obtained from plasma or prepared by using the genetic recombination technique, and efficiently prolongs life-span of DIC patients where the basal disease is malignant tumor, especially malignant tumor in hematopoietic organs. In particular, the medicament may reduce adverse side effects of chemotherapeutics in chemotherapy of malignant tumor to enhance efficacy of said therapy and improve prognostic survival of patients suffering from malignant tumor.

摘要翻译： 提供了一种用于改善恶性肿瘤治疗预后生存的药物，可以改善基底疾病是恶性肿瘤，特别是造血器官恶性肿瘤的DIC患者的预后生存。 根据本发明的药物包含作为主要活性成分的由血浆获得或通过使用遗传重组技术制备的活化蛋白C，并有效延长了基础疾病是恶性肿瘤，特别是恶性肿瘤的DIC患者的寿命 在造血器官。 特别地，药物可以减少化学治疗剂在恶性肿瘤化疗中的不良副作用，以增强所述治疗的疗效并改善恶性肿瘤患者的预后。

公开(公告)号：US07033994B2

公开(公告)日：2006-04-25

申请号：US10168727

申请日：2000-12-21

申请人： Tatsuya Araki ,  Kazuhiko Tomokiyo ,  Yasushi Nakatomi ,  Kaori Teshima ,  Tomoko Watanabe ,  Tomohiro Nakagaki

发明人： Tatsuya Araki ,  Kazuhiko Tomokiyo ,  Yasushi Nakatomi ,  Kaori Teshima ,  Tomoko Watanabe ,  Tomohiro Nakagaki

IPC分类号： A61K38/00 ,  A61K35/14 ,  A61K35/16

CPC分类号： A61K38/37 ,  Y10S514/802 ,  Y10S514/834

摘要： The present invention provides a pharmaceutical composition for treatment and prevention of bleeding disorders caused by platelet disorders, not caused by defect in blood coagulation factors or von Willebrand Factor but caused by reduction of circulating platelet count or platelet dysfunction, said composition comprising a hemostatic effective amount of Factor VIII and/or von Willebrand Factor. Also provided is a method for treating said bleeding, comprising administering a hemostatic effective amount of Factor VIII and/or von Willebrand Factor to patients suffering from bleeding disorders caused by platelet disorders.

公开(公告)号：US06855319B1

公开(公告)日：2005-02-15

申请号：US09807459

申请日：1999-08-13

申请人： Hiromi Ikadai ,  Ikuo Igarashi ,  Naoyoshi Suzuki ,  Hideyuki Nagasawa ,  Kozo Fujisaki ,  Takeshi Mikami

发明人： Hiromi Ikadai ,  Ikuo Igarashi ,  Naoyoshi Suzuki ,  Hideyuki Nagasawa ,  Kozo Fujisaki ,  Takeshi Mikami

IPC分类号： C07H21/02 ,  C07H21/04 ,  C07K14/44 ,  C07K16/20 ,  C12N1/21 ,  C12N15/30 ,  G01N33/569 ,  A61K39/002 ,  A61K39/015 ,  C07K1/00

CPC分类号： G01N33/56905 ,  C07K14/44 ,  C07K16/20 ,  Y10S530/822

摘要： The present invention provides a gene encoding a protein from merozoite of Babesia caballi, a recombinant protein of Babesia caballi, and an antibody capable specifically binding to a 48 kDa protein of rhoptry of Babesia caballi merozoite. In accordance with the present invention, it is possible to stably prepare the 48 kDa protein of rhoptry of Babesia caballi and the gene encoding said protein in a large amount with the recombinant DNA technique. The present invention also provides a method for diagnosing equine babesiasis which comprises either specifically detecting anti-Babesia caballi antibody present in equine blood by using the recombinant protein of present invention as an .antigen or detecting the presence of Babesia caballi merozoite in equine blood by using the antibody of the present invention.

摘要翻译： 本发明提供了编码来自巴贝虫（Babesia caballi）的重组蛋白的巴贝虫（Babesia caballi）的裂殖子的蛋白质和能够特异性结合巴贝虫裂殖子的48kDa蛋白质的抗体的基因。 根据本发明，可以通过重组DNA技术稳定地制备巴贝氏菌的48kDa蛋白质和大量编码所述蛋白质的基因。 本发明还提供了一种用于诊断马贝氏病的方法，其包括通过使用本发明的重组蛋白作为抗原特异性检测存在于马血中的抗巴贝虫抗体，或通过使用马血检测胎儿巴马裂殖子的存在 本发明的抗体。